ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

California and New Jersey Associations Lead Multi-State Letter of Support for FDA S.O.S Act
Facebook
Twitter
LinkedIn

May 21, 2015

In collaboration with San Diego-based Biocom and three New Jersey-based associations (HINJ, N.J. Bio and Innovation New Jersey), CLSA led a multi-state and regional life sciences association letter of endorsement for H.R. 1078, the FDA Safety Over Sequestration (SOS) Act, legislation to exempt industry-paid user fees from any future across-the-board spending cuts (sequestration). CLSA worked closely with our national association partners AdvaMed, BIO, PhRMA and MDMA to garner strong life sciences state and regional association support for this effort. A total of 40 organizations signed the letter of endorsement, which was well-received and appreciated by the bill sponsors, Reps. Anna Eshoo (D-Silicon Valley) and Leonard Lance (R-N.J.). (A similar letter last congress was supported by 33 state and regional associations).

Given the possibility that sequestration may be triggered again in FY2016 – just as the next round of user fee negotiations commence – it is critically important that Congress act now to ensure FDA’s ability to access user fees is unrestricted and unaffected by potential across-the-board spending cuts. These funds are critical not only for FDA to meet its Congressionally-mandated product review responsibilities, but for sustaining biomedical investment, innovation and improvements in patient care. CLSA will continue to work with the California delegation to advocate for swift consideration of the legislation.

You can view a copy of the letter here. Click here to view an op-ed in The Hill from Todd Gillenwater, CLSA’s Executive Vice President of Advocacy & External Relations, on the need to protect FDA user fees from sequestration.